

ABSTRACT OF THE DISCLOSURE

The present invention is directed to a method of treating a patient with amyotrophic lateral sclerosis using an effective
5 amount of soluble Fcγ receptors. The soluble Fcγ receptors of the invention are specific for immunoglobulin G of under-class 1 (IgG1) and/or 3 (IgG3).